EPCAT II is a multicenter, double-blind RCT comparing aspirin with rivaroxaban for extended VTE prophylaxis after total hip or knee arthroplasty. All patients first received 5 days of rivaroxaban, then were randomized to continue rivaroxaban or switch to aspirin 81 mg. It asks whether a cheap antiplatelet drug can match a direct oral anticoagulant for postdischarge prophylaxis.
For VTE prophylaxis after elective hip or knee arthroplasty, this trial supports a practical protocol: rivaroxaban 10 mg daily for the first 5 postoperative days, then aspirin 81 mg daily for extended prophylaxis (9 days for knees, 30 days for hips).
The clinical payoff is cost and convenience. Aspirin is generic, oral, needs no monitoring, and matched the anticoagulant for both efficacy and bleeding. For boards, anchor the framework: guidelines call for at least 14 days of prophylaxis, extendable to 35 days, with extended duration most valuable after THA. Rivaroxaban acts as a direct factor Xa inhibitor.
A key pitfall: do not stack a second aspirin dose on patients already taking long-term aspirin. EPCAT II found no added VTE protection and a bleeding trend. Remember the design caveat. Because aspirin only followed a rivaroxaban lead-in, this trial does not prove aspirin alone, started immediately postoperatively, is equivalent to full-course anticoagulation.
EPCAT II is a multicenter, double-blind RCT comparing aspirin with rivaroxaban for extended VTE prophylaxis after total hip or knee arthroplasty. All patients first received 5 days of rivaroxaban, then were randomized to continue rivaroxaban or switch to aspirin 81 mg. It asks whether a cheap antiplatelet drug can match a direct oral anticoagulant for postdischarge prophylaxis.
For VTE prophylaxis after elective hip or knee arthroplasty, this trial supports a practical protocol: rivaroxaban 10 mg daily for the first 5 postoperative days, then aspirin 81 mg daily for extended prophylaxis (9 days for knees, 30 days for hips).
The clinical payoff is cost and convenience. Aspirin is generic, oral, needs no monitoring, and matched the anticoagulant for both efficacy and bleeding. For boards, anchor the framework: guidelines call for at least 14 days of prophylaxis, extendable to 35 days, with extended duration most valuable after THA. Rivaroxaban acts as a direct factor Xa inhibitor.
A key pitfall: do not stack a second aspirin dose on patients already taking long-term aspirin. EPCAT II found no added VTE protection and a bleeding trend. Remember the design caveat. Because aspirin only followed a rivaroxaban lead-in, this trial does not prove aspirin alone, started immediately postoperatively, is equivalent to full-course anticoagulation.